PMA increases M3 muscarinic receptor levels and decreases retinal cells proliferation through a change in the levels of cell-cycle regulatory proteins  by Braga, Luis Eduardo Gomes et al.
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PMA  changes  p53,  p21  and  cyclin  D1  levels.
PMA  mimics  the  increase  in M3  levels  observed  in normal  tissue  development.
The  p21  levels  peak  in  P7  and  is concomitant  with  the  decrease  in cell proliferation.
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Protein  kinase  C  (PKC)  pathway  plays  important  roles  in different  phenomena  in  nervous  system  devel-
opment.  Our  previous  data  demonstrated  that  phorbol  12-myristate  13-acetate  (PMA)  treatment,  a PKC
activator, for  48 h  decreases  retinal  cells  proliferation  by  a  mechanism  mediated  by muscarinic  receptor
activation,  involving  a decrease  in M1 receptors  levels.  The  aim  of this  work  was  to analyze  how  PMA
interferes  in  the  levels  of cell  cycle  control  proteins  p53,  p21  and  cyclin  D1  and  also  to  investigate  its
inﬂuence  on M3  receptor  levels.  Our  results  show that PMA  (50  ng/mL)  produces  a signiﬁcant  increaseyclin D1
53
21
at
in  p21  and p53 levels,  decreases  cyclin  D1  levels,  and  also  enhances  M3 receptors  levels  in  cell  cultures.
Evaluating  the  postnatal  retinal  tissue  development  until  30  days,  we  observed  that  tissue  differentiation
is  accompanied  by  an  increase  in  M3 and  p21  levels.  Based  on our  results  we  suggest  that PMA  treatment
is  promoting  a change  in  muscarinic  receptors  expression  mimicking  the  pattern  observed  during  tissue
differentiation,  indicating  that PMA  is probably  accelerating  the  cholinergic  differentiation  in rat  retinal
cell  cultures.. Introduction
PKC was discovered in 1977 [12] in studies using rat brain
xtracts. This enzyme is a member of the serine/threonine phos-
hotransferases family and is divided into three subfamilies:
onventional (, I, II and ), novel (, ,  and ) and atypical
	 and 
). The PKC isoenzymes activate different intracellular cell
ignaling pathways [10] involved in many biological processes such
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as cell proliferation and differentiation, neural plasticity, immunity
and cell death [27]. It was also observed that PKC can limit the
proliferation of certain cancer cell lineages [17,33].
PMA is a phorbol ester isolated from the seed oil of Croton tiglium
and other plants of the Euphorbiaceae family [3]. It is an activa-
tor of the conventional and novel PKC classes. It is well known
that the PMA  tumor-promoter activity is associated with sustained
activation of PKC, compared with that of the physiological activa-
tor diacylglycerol [22]. However, in other systems, PMA  treatment
decreases cell proliferation, both during normal development and
in cancer cell lines. This effect is attributed to PKC’s ability to modu-
late the expression of transcription factors and cell cycle regulatory
proteins [3,9,33].The balance between cell proliferation and differentiation is
regulated by a mechanism that involves the cell cycle control.
One important way to inﬂuence this balance is by changing the
expression of key regulatory proteins of the cell cycle (cyclins,
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yclin-dependent kinases and inhibitors of cyclin-dependent
inases) through transcription alteration and also by turnover
odiﬁcation. During the development of the nervous system,
ells undergo a period of intense proliferation where cyclins and
yclin-dependent kinases regulate cell cycle progression. At the
ppropriate time, speciﬁc cell signaling pathways interfere with
he expression and activity of these proteins inhibiting cell cycle
rogression through a pause on the G1 phase. The cells enter then
n the quiescent G0 phase where the differentiation process takes
lace [34].
It has been demonstrated in various regions of the nervous
ystem that PKC is able to mediate the release of neurotransmit-
ers (as acetylcholine) [16,38]. Acetylcholine is widely distributed
hroughout the central nervous system [2] and plays a critical role in
erebral cortical development, cortical activity, cerebral blood ﬂow
ontrol, sleep–wake cycle as well as in modulating cognitive per-
ormances [31]. The muscarinic acetylcholine receptors (mAChR)
re divided in ﬁve subtypes (M1–M5). Members of the “M1-like”
amily (M1, M3,  and M5)  are associated with the Gq protein and
hosphatidylinositol turnover. In contrast, members of the “M2-
ike” family (M2  and M4)  are generally linked to inhibition of
denylyl cyclase activity [18].
We  previously showed that PMA  treatment for 48 h decreases
etinal cells proliferation in culture, an effect mediated mAChR acti-
ation and polypeptide release [29]. We also demonstrated that
MA treatment decreases M1  receptor expression, and that this
ffect mimics the decrease that occurs during the normal develop-
ent of retinal tissue [30]. Based on these previous results, in this
ork we analyzed the levels of three important regulatory proteins
f the cell cycle p53, p21 and cyclin D1, as well as the levels of M3
eceptor following PMA  treatment of retinal cell cultures. We  also
nvestigated the levels of M3 receptor and p21 during the postnatal
evelopment of retinal cells.
. Materials and methods
.1. Chemicals
Medium 199 and fetal calf serum were purchased from
ibco (USA). PMA, rabbit anti-M3 antibody, poly-l-ornithine, l-
lutamine, penicillin and streptomycin sulfate were obtained from
igma (USA). Trypsin was  purchased from Worthington (USA).
ulture dishes were obtained from TPP (Switzerland). Hyper-
lm, acrylamide, methylene bis acrylamide, 2-mercaptoethanol,
econdary antibody anti-rabbit HRP-linked, ECL Western blot
etection kit, PVDF membrane and [methyl-3H]-thymidine were
btained from Amersham (USA). Sodium dodecyl sulfate, Tris
Tris[hydroxymethyl]aminomethane) and ammonium persulfate,
ere purchased from USB (USA). Glycine was obtained from Queel
Brazil). Tween 20, comassie blue, trichloroacetic acid (TCA) and
lycerol were obtained by VETEC (Brazil). Rabbit anti-cyclin D1
as obtained from Cell Signaling Technology (USA). Secondary
abbit anti-goat HRP linked, goat anti-actin (C-11) antibody, rab-
it anti-p53 antibody and bovine serum albumin (BSA) and rabbit
nti-p21 antibody were obtained from Santa Cruz Biotechnology
USA). TEMED and molecular weight standard were obtained from
nvitrogen (USA). Methanol was obtained from J.T. Baker (USA).
.2. Retinal cultures
Cultures containing neurons, glial cells and mostly neuroblasts
ere prepared using techniques previously described [28]. Postna-
al Lister Hooded rats (P0–P2) were used.
Cells were placed on Petri dishes previously treated with poly-
-ornithine (25 g/mL) at a plating density of 105 cells/cm2. The Letters 550 (2013) 29– 34
cultures were maintained in a humidiﬁed atmosphere of 5% CO2
and 95% air at 37 ◦C for 48 h. All procedures using animals were
approved by the local committee for animal care and experimenta-
tion (CEPA-projects #00196-10). All efforts were made to minimize
the number of experimental animals and their suffering.
2.3. Western blot
The levels of M3  receptors, p53, cyclin D1, p21 and actin were
determined [30]. Actin was  used as a loading control protein.
Membranes were incubated with rabbit anti-M3 antibody
(0.8 g/ml), anti-p53 antibody (1:200), anti-cyclin D1 antibody
(1:1000), anti-p21 antibody (1:500) or goat anti-actin (C-11) anti-
body (1:500). Membranes were washed in TBS and then exposed
to HRP-conjugated secondary anti-rabbit (1:10,000) or anti-goat
IgG antibody (1:5000) at room temperature for 60 min. Detection
was performed on X-ray ﬁlm (hyperﬁlm) using chemiluminescence
system (ECL). The density of protein bands was  analyzed by densit-
ometry with Scion Image. The mean value for the control was set
at 100%.
2.4. [3H]-thymidine incorporation
Retinal explants (P0–P14) were incubated in medium without
serum in the presence of 1 Ci/mL of [methyl-3H]-thymidine and
maintained in a shaker at 60–70 rpm for 60 min  at 37 ◦C, in atmo-
sphere of 95% air and 5% CO2. Then explants were washed three
times with medium without serum to remove the [methyl-3H]-
thymidine not incorporated. Following, the medium was removed
and 200 L of 1 N NaOH were added to each sample and maintained
for 15 min. Subsequently, 3 mL  of MilliQ water and 600 L of 50%
TCA were added. After 30 min  each sample was ﬁltered in What-
man  GF/B ﬁlters under negative pressure. The ﬁlters were placed
at 100 ◦C for 30 min  to dry. The radioactivity was  then determined
by liquid scintillation.
2.5. Statistical analysis
The overall statistical analysis was  ﬁrst obtained by one-way
analysis of variance (ANOVA). Statistical signiﬁcance of all pairs of
multiple groups of data was assessed by Newman–Keuls compar-
ison test. To analyze two  experimental groups we used Student’s
t-test. A P value <0.05 was  considered statistically signiﬁcant.
3. Results
3.1. PMA effect on the levels of p21, p53 and cyclin D1
To understand the mechanism involved in the anti-proliferative
effect of PMA  on retinal cells we evaluated its inﬂuence on the levels
of three important proteins involved in the regulation of the tran-
sition of G1 to S phases of cell cycle: p21, p53 and cyclin D1 [14,42].
Fig. 1 shows that PMA  treatment of retinal cell cultures for 48 h
produces an increase (28% compared to the control) in p21 levels
(Fig. 1A, B) and an increase in p53 levels (57% compared to the con-
trol) (Fig. 1C, D). Following, we  investigate the effect of PMA  on the
expression of cyclin D1. Our data show that retinal cells treated with
PMA  50 ng/mL exhibit a 54% decrease in cyclin D1 levels (Fig. 1E, F).
3.2. Retinal tissue: proliferation pattern and p21 levelsWhen we  investigated the levels of p21 during the normal post-
natal development of retinal tissue (P0–P30), we observed a gradual
increase in p21 levels up to P7, when it reaches a 57% increase com-
pared to P0. In P14, p21 levels decreases returning to P0 levels.
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ultures and (E, F) PMA  decreases cyclin D1 levels in retinal cells. Signals are expres
ontrol.
hese levels were maintained until P30 (Fig. 2A, B). We  also evalu-
ted the proliferation pattern of retinal tissue during the postnatal
ays 0–14. Fig. 2C shows that there is a dramatic decrease in retinal
ells proliferation in P7 and P14, when it is well known that the tis-
ue achieved its mature developmental phenotype [4,39]. During
he developmental postnatal stages the cellular populations of the
etinas changes gradually. The neuroblast cells differentiate into
eurons and glial cells present in the mature tissue [19].
.3. M3  receptors levels in normal retinal development and in
ulture cells treated with PMA
Our previous results demonstrated that the decrease in cell pro-
iferation mediated by PMA  treatment is dependent on muscarinic
eceptor activation, and also that it induces a signiﬁcant decrease in
1 receptors levels [29,30]. As literature shows that M3 receptors
re involved in the process of cell differentiation [13,20], we analyze
f PMA  treatment is also interfering the levels of the M3  acetyl-
holine receptor type. We  ﬁrst analyzed the levels of M3 receptors
n retinal cell cultures treated with PMA  for 48Hs. Fig. 3A and B
how that 50 ng/mL PMA  treatment induces a 102% increase in the
3 receptor levels. Following, we evaluated the expression of M3
eceptors during normal development of postnatal retinal tissue,
sing rat retinal tissue on postnatal days 0, 4, 7, 14 and 30 (P0–P30).s p21 levels in retinal cells cultures, (C, D) PMA  increases p53 levels in retinal cells
 arbitrary units (% of control) as mean ± S.E.M (n = 3–4). *P < 0.001 compared to the
Fig. 3C and D shows that there is a gradual increase in M3  expression
during retinal development, and we can observe that the increase
in the expression of M3  is of approximately 66% in P30 tissue, when
compared to P0.
4. Discussion
The regulation of the transition of G1 to S phases of the cell cycle
is the goal of different signaling cascades triggered by extracellular
signals that inﬂuences cell proliferation, including PKC activation
[6]. p53 is a transcription factor that negatively regulates the cell
cycle by induction of p21, a cdk inhibitor. p21 leads to the inhi-
bition of the complex cyclinD/cdk4/6, that regulates G1/S phase
transition [14]. It was  demonstrated that DNA damage activates
the transcription of p21 in a p53-dependent pathway [11]. We
showed that PMA  treatment exerts the effect of decreasing cell pro-
liferation of retinal cells by changing p21, p53 and cyclin D1 levels.
Literature shows that p53 can be phosphorylated by PKC [6] and
that p53 phosphorylation is important for its DNA binding activity
[15,25,37]. Corroborating our results, it was observed in human
endometrial cancer cells that treatment with growth hormone-
releasing hormone antagonist induces an increase in p53 and
p21 expressions via PKC activation [41]. Literature demonstrates
that PKC activation is able to induce p53 accumulation [1,23].
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Fig. 3. (A, B) PMA  increases the levels of M3 receptor in retinal cell cultures afterig. 2. (A, B) p21 levels in retinal tissue (P0–P30), n = 3–5. (C) Retinal cells prolifer-
tion during normal tissue development (P0–P14), n = 3–9. Signals are expressed in
rbitrary units (% of control) as mean ± S.E.M. *P < 0.001 compared to the control.
n human hepatoma cells PMA  induced a transient increase p53
xpression, observed from 30 min  of incubation until 180 min, and
 posterior fall in p53 expression observed after 6 h of incubation
32]. However, it is also described the regulation of p21 expression
y a p53 independent mechanism, and, indeed, PMA  effect on cell
rowth inhibition can also be mediated by this mechanism [24,36].
e believe that PMA  can induce G1 arrest through different mech-
nisms depending on cell type and possibly by the developmental
tage. It could be explained by the presence of different PKC iso-
orms in the same cell, by the complexity of the signaling pathways
hat can be triggered and also by the changes in isoforms expression
ccording to the developmental stage. Indeed, it was demonstrated
n yeast that PKC activation can induce both positive and negative
nﬂuence on p53 depending on the PKC isoform activated [7].
Although PMA  induces PKC downregulation, in our previous
ork [29] we demonstrated that the anti-proliferative effect of PMA
s dependent on PKC activation. Literature shows the expression
f different PKC isoenzymes in retinal tissue. It was demonstrated
KC, ,  and  in bipolar cells, PKC in Müller cells, PKC	 in the
nner segments of photoreceptor and PKC 
/ in horizontal cells
40]. Our next step will be to identify the PKC isotype involved in
he PMA  effect.
Cyclin D1 forms a complex with CDK4/6 leading to phosphory-
ation and subsequent inactivation of the retinoblastoma protein
pRb). The Rb inactivation increases cell proliferation because it
romotes the release of E2F, a transcription factor that has a
ole on the progression of the G1 to S phase [35,42]. Literature48  h. (C, D) M3  receptor levels in retinal tissue (P0–P30). Signals are expressed in
arbitrary units (% of control) as mean ± S.E.M (n = 3–4). *P < 0.001 compared to the
control.
demonstrated that the decrease in cyclin D1 levels induces an
increase in the duration of G1 phase, a reduction in proliferation
and a loss of carcinogenicity in nude mice [5]. The decrease in
cyclin D1 levels induced by PMA  treatment is in accordance to the
anti-proliferative effect observed with this treatment.
Analyzing our results we  conclude that the anti-proliferative
effect of PMA  in cultured retinal cells of newborn rats is exerted by a
signaling pathway initiated by PKC activation that interferes in cell
cycle progression by a mechanism that involves the change in p21,
p53 and cyclin D1 levels. Meng and collaborators also demonstrated
that tetrandrine, an antitumor alkaloid, exerts its effect on inhibi-
ting the proliferation of human colon carcinoma cells by increasing
p53 and p21 and decreasing cyclin D1 levels, leading to the inhibi-
tion of the progression of G1 phase [21]. It was  also demonstrated
that PMA  treatment of lung cancer cells induces cell growth arrest
by a mechanism that involves an increase in p21 levels [33].
Our results show that the levels of p21 increases from P0 to P7,
concomitant with the differentiation process of retinal tissue, and
we observe the falling in p21 levels from P7 to P14, exactly when
the decrease in retinal tissue proliferation occurs. It is interesting
to note that the 48 h PMA  treatment is mimicking this same pattern
in retinal cells culture. This fact corroborates to our hypothesis that
PMA  is stimulating the differentiation of retinal cells.
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As our previous work demonstrated that muscarinic receptor
ctivation is an essential step on the anti-proliferative PMA effect
nd that it induces a decrease in M1  receptor levels [29,30], we
upposed that PMA  treatment could be inducing a change in the bal-
nce between acetylcholine receptor subtypes levels. The present
ork demonstrates that the chronic activation of PKC by PMA  trigg-
rs a signiﬁcant and opposite effect on the expression of M1  and
3 receptors subtypes, as it induces an increase in M3  receptor
evels that contrasts with the decrease in M1  receptor previously
bserved [30]. It is interesting to note that the PMA  effect on the lev-
ls of M1  and M3  mimics the changes in the levels of these receptors
hat occur during normal development accelerating the muscarinic
1 and M3  receptors pattern change that normally occurs during
issue maturation.
Muscarinic receptors activation is involved in aspects concern-
ng neuronal differentiation and also that there is a change in the
ubtypes expression during tissue development. Data from liter-
ture showed that carbachol, an acetylcholine analog, produces
eurite outgrowth in hippocampal neurons by activating M3  recep-
ors in astrocytes [13]. Muscarinic receptors are also present in
lial cells. It was seen that oligodendrocyte cell cultures express
ll muscarinic receptor subtypes being M3  representing the high-
st level both in progenitor and mature oligodendrocytes. They also
bserved that in mature oligodendrocytes there was  a decrease in
he expression of M1,  M3  and M4  immunoreativities [8,26]. In chick
etina, it was observed an increase in M3  receptor expression later
n the development [20]. These data are in accordance with our ﬁnd-
ngs of the change in muscarinic receptor subtypes levels during
issue development.
In conclusion, our results demonstrate that PMA  treat-
ent induces a modulation of the phenomenon of prolifera-
ion/differentiation of rat retinal cells in culture by controlling the
evels of p21, in a p53 dependent manner. It also promotes a change
n the balance between M1  and M3  receptors levels mimicking the
attern observed in the mature tissue.
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